COMMUNIQUÉS West-GlobeNewswire

Nanobiotix participera à des conférences investisseurs en mars
06/03/2024
PARIS et CAMBRIDGE, Mass., 06 mars 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06/03/2024
Highlights TTX-MC138’s Path from Target Discovery to the Clinic BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating [...]
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
06/03/2024
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage [...]
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
06/03/2024
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics [...]
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
06/03/2024
BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/03/2024
CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2024
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
06/03/2024
Record full year 2023 revenue of $148.7 million increased 22% compared to prior year WARSAW, Ind., March 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company [...]
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
06/03/2024
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
06/03/2024
- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 – - CONNECT2-EDO51 [...]
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
06/03/2024
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
06/03/2024
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and [...]
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
06/03/2024
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year [...]
Nurix Therapeutics to Participate in Upcoming Investor Conferences
06/03/2024
SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]
ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination
06/03/2024
LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today made the oral presentation “HepB-CpG Vaccine is Superior to HepB-alum in People [...]
Health Systems near their breaking point. Labor costs continue to increase while dollars collected from payers decrease.
06/03/2024
CHICAGO, March 06, 2024 (GLOBE NEWSWIRE) -- Eighty four percent of health systems cite lower reimbursement from payers as a top cause of low operational margins, according to a report published by the Healthcare [...]
Merus annonce la publication d’un résumé qui sera présenté à la réunion annuelle 2024 de l’AACR : Zeno est efficace dans le traitement des modèles de cancer avec une forte expression du gène NRG1
06/03/2024
Présentation de l’affiche : lundi 8 avril 2024, de 9 h à 12 h 30, heure du Pacifique UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 06 mars 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société [...]
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
06/03/2024
PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and [...]

Pages